Increased Targeting Area in Tumors by Dual-Ligand Modification of Liposomes with RGD and TAT Peptides
Modification with polyethylene glycol (PEGylation) and the use of rigid phospholipids drastically improve the pharmacokinetics of chemotherapeutics and result in more manageable or reduced side-effects. A major drawback is retarded cellular delivery of content, which, along with tumor heterogeneity,...
Main Authors: | Mohamadreza Amin, Mercedeh Mansourian, Peter C. Burgers, Bahareh Amin, Mahmoud Reza Jaafari, Timo L. M. ten Hagen |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-02-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/2/458 |
Similar Items
-
Liposomal Drug Delivery Systems for Cancer Therapy: The Rotterdam Experience
by: Mohamadreza Amin, et al.
Published: (2022-10-01) -
Recent Preclinical and Clinical Progress in Liposomal Doxorubicin
by: Kenan Aloss, et al.
Published: (2023-03-01) -
Efficient Delivery of Gemcitabine by Estrogen Receptor-Targeted PEGylated Liposome and Its Anti-Lung Cancer Activity In Vivo and In Vitro
by: Huan Tang, et al.
Published: (2023-03-01) -
Recent Progress of RGD Modified Liposomes as Multistage Rocket Against Cancer
by: Afsana Sheikh, et al.
Published: (2022-01-01) -
EGFR Targeting of Liposomal Doxorubicin Improves Recognition and Suppression of Non-Small Cell Lung Cancer
by: Moles E, et al.
Published: (2024-04-01)